A Study of the Equivalent Effectiveness of 400 Mcg Mometasone Furoate Using Two Different Dry Powder Inhalers in Moderate Asthmatics (Study P04828)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00521599
First received: August 27, 2007
Last updated: October 18, 2013
Last verified: October 2013
  Purpose

This study is a placebo-controlled study with 8-weeks of double-blind treatment of mometasone furoate dry powder inhaler (MF DPI) 200 mcg twice daily (BID) using two different inhalers, preceded by the Screening Period and by 2 weeks of open-label treatment with one inhalation of MF DPI 200 mcg twice daily in corticosteroid-dependent asthmatic subjects. The objective of this study is to evaluate the therapeutic equivalency of the 100 mcg and 200 mcg MF DPIs when providing the same total daily dose (400 mcg/day).


Condition Intervention Phase
Asthma
Drug: Mometasone furoate dry powder inhaler
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Study of the Therapeutic Equivalency of MF DPI 100 Mcg and 200 Mcg Inhalers in Corticosteroid-Dependent Subjects With Moderate Asthma

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Change From Baseline in the Average AM Peak Expiratory Flow (PEF) Over the 7 Days of Week 8. [ Time Frame: Baseline and Week 8 End ] [ Designated as safety issue: No ]
    Week 8 End = The last 7 days of data with the last day within the range of Days 51 to 64.


Enrollment: 672
Study Start Date: May 2007
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MF DPI 2 x 100 mcg BID
2 inhalations of mometasone furoate dry powder inhaler (MF DPI) 100 mcg plus 1 inhalation of placebo matching MF DPI 200 mcg twice daily (BID) for 8 weeks
Drug: Mometasone furoate dry powder inhaler
Other Name: Asmanex
Drug: Placebo
Other Name: placebo
Experimental: MF DPI 1 x 200 mcg BID
1 inhalation of mometasone furoate dry powder inhaler (MF DPI) 200 mcg plus 2 inhalations of placebo matching MF DPI 100 mcg twice daily (BID) for 8 weeks
Drug: Mometasone furoate dry powder inhaler
Other Name: Asmanex
Drug: Placebo
Other Name: placebo
Placebo Comparator: Placebo
2 inhalations of placebo matching mometasone furoate dry powder inhaler (MF DPI) 100 mcg plus 1 inhalation of placebo matching MF DPI 200 mcg twice daily (BID) for 8 weeks
Drug: Placebo
Other Name: placebo

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

18 years of age, either sex, any race, with a diagnosis of asthma of at least 12 months' duration.

  • Must be on a stable regimen of a medium daily dose of ICS for at least 4 weeks immediately prior to Screening. Medium daily doses of ICS are:

    • >500 to 1000 mcg beclomethasone CFC
    • >250 to 500 mcg beclomethasone HFA
    • >600 to 1000 mcg budesonide DPI
    • >1000 to 2000 mcg flunisolide
    • >250 to 500 mcg fluticasone
    • 400 mcg MF
    • >1000 to 2000 mcg triamcinolone acetonide.
  • Must have a documented reversibility test obtained within 12 months prior to signing the informed consent form. Otherwise, to document a diagnosis of asthma and ensure the subject's responsiveness to bronchodilators, one of the following methods can be used at the Screening Visit, or thereafter, but prior to the Baseline Visit:

    • An increase in absolute FEV1 of >=12% and >=200 mL within 30 minutes of administration of 4 puffs of albuterol.
    • A PEF variability of >20%, expressed as a percent of the best and lowest morning pre-bronchodilator PEF over at least 1 week.
    • A diurnal variation in PEF of >20% based on the difference between the pre-bronchodilator AM value and the post-bronchodilator value from the evening before, expressed as a percentage of the mean daily PEF value any day during the Run-in Period.
  • At Screening and Baseline, the subject's FEV1 must be >=60% predicted, when all restricted medications have been withheld for the appropriate intervals. If, based on the clinical judgment of the investigator, there is no harm in changing the subject's asthma therapy, subjects on LABAs must be willing to discontinue the LABA and be transferred to open-label treatment with MF MDI 200 mcg BID for 2 weeks prior to randomization.
  • Clinical laboratory tests conducted at the Screening Visit must be within normal limits or clinically acceptable to the investigator/sponsor before the subject is instructed to start using open-label MF DPI run-in medication. A chest x-ray performed at the Screening Visit or any type of chest imaging within 12 months prior to the Screening Visit must be clinically acceptable to the investigator.
  • A female of childbearing potential must be using a medically acceptable, adequate form of birth control. This includes: 1) hormonal contraceptives as prescribed by a physician (oral combined, hormonal implant); 2) medically prescribed IUD; 3) condom in combination with a spermicide (double-barrier method); 4) monogamous relationship with a male partner who has had a vasectomy. The subject must have started this birth control method at least 3 months prior to Screening (with the exception of condom in combination with spermicide), and must agree to continue its use for the duration of the study. A subject of childbearing potential who is not currently sexually active must agree and consent to using a medically acceptable method should she become sexually active during the course of this study. Women who have been surgically sterilized or are at least 1 year postmenopausal are not considered to be of childbearing potential. A subject of childbearing potential must have a negative serum pregnancy test at Screening.

Exclusion Criteria:

  • A change in absolute FEV1 of >20% at any time from the Screening Visit up to and including the Baseline Visit.
  • A clinical asthma exacerbation (defined as a deterioration of asthma that results in emergency treatment, hospitalization, or treatment with additional, excluded asthma medication at any time from the Screening Visit up to and including the Baseline Visit).
  • Treatment in the emergency department or admission to the hospital for an asthma exacerbation 12 months prior to Screening.
  • An upper or lower respiratory tract infection within the 4 weeks of to Screening. Visits can be rescheduled to meet this requirement.
  • Evidence of clinically significant oropharyngeal candidiasis at Baseline with or without treatment. If there is evidence of oropharyngeal candidiasis at Screening and/or during the MF DPI Run-in Period, the subject may be treated as appropriate and the Baseline Visit can be scheduled upon resolution. If there is evidence of oropharyngeal candidiasis at the Baseline Visit, the subject may be treated as appropriate and the visit can be rescheduled upon resolution.
  • A smoker or ex-smoker and has smoked within the previous year or has had a cumulative smoking history >10 pack-years.
  • Requires more than twelve inhalations of albuterol or more than 2 treatments with nebulized beta-agonists on any 2 consecutive days during the Run-in Period.
  • Ever required mechanical ventilation secondary to an asthma exacerbation.
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00521599     History of Changes
Other Study ID Numbers: P04828
Study First Received: August 27, 2007
Results First Received: February 26, 2010
Last Updated: October 18, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Mometasone furoate
Anti-Allergic Agents
Therapeutic Uses
Pharmacologic Actions
Anti-Inflammatory Agents

ClinicalTrials.gov processed this record on April 17, 2014